Vesugen (KED, T-38) Side Effects: What Limited Data Show#

There is no PubMed-indexed human safety dataset for Vesugen, and the side-effect profile below is built from the preclinical 5xFAD mouse study (Khavinson 2021; PMID 34071923)¹, research-chemical-vendor literature, community self-reports, and the Khavinson group's Russian-language clinic summaries. Last verified June 4, 2026.

Reported Side Effects#

Local / Mild#

• Injection-site reactions: mild erythema, tenderness, or transient swelling at subcutaneous injection sites (community reports)
• Headache: sporadic mild headache during the first days of a course (community reports)
• 5xFAD mouse study reported no overt adverse effects at 400 mcg/kg/day intraperitoneal injection -- but this was a 2-month study in mice with no human-grade monitoring¹

Theoretical Concerns#

• Cancer biology overlap. The proposed binding partners in PMID 34071923 docking (CASP3, NES, GAP43, APOE, SOD2, PPARA, PPARG) include genes implicated in cancer biology. Long-term effects of modulating these promoters have not been studied for Vesugen specifically.
• Vascular endothelial effects + anticoagulation. If the proposed vascular endothelial effects (SIRT1 induction, endothelial function modulation) are operative, theoretical interactions with anticoagulants and antiplatelet agents cannot be excluded.
• SIRT1-pathway interactions. Concurrent use with other SIRT1-targeting interventions (resveratrol, NAD precursors like NR or NMN) has not been studied.
• Immunogenicity. Short peptides can in principle elicit immune responses; antibody-development data for Vesugen are not published.

Contraindications#

Vesugen should not be used in:

• Pregnancy and breastfeeding (no safety data; no indication)
• Children and adolescents (no indication; no safety data)
• Active malignancy or known precancerous lesions (theoretical concern)
• People with known hypersensitivity to short peptides
• People enrolled in unrelated clinical trial protocols

Drug Interactions#

No drug-drug interactions have been characterised in PubMed-indexed literature. Theoretical caution is warranted with:

• Anticoagulants and antiplatelet agents (vascular endothelial mechanism)
• SIRT1-targeting interventions (resveratrol, NAD precursors)
• Concurrent multi-peptide bioregulator protocols
• Cancer therapies (any agent affecting transcriptional state warrants oncology supervision)

Monitoring Recommendations (For Anyone Using Vesugen Despite the Gaps)#

If someone chooses to use Vesugen outside a clinical trial context, the minimal monitoring posture should include:

• Baseline cardiovascular evaluation (blood pressure, lipid panel, if vascular use is the rationale)
• Symptom diary
• Immediate clinician consultation for any unexpected symptom (chest pain, palpitations, bleeding, allergic-type reaction)

Bottom Line#

The Vesugen side-effect profile is dominated by data absence. The available preclinical and community reports suggest a mild profile, but the methodological quality is far below the standard required for safety characterisation. Treat Vesugen as an investigational compound with an undefined adverse-event profile.

References#

Related Reading#

• Vesugen research and evidence base
• Vesugen dosing protocols
• Vesugen risks and legal status
• Pinealon side-effects (co-administered in PMID 34071923)
• Prostamax side-effects

Footnotes#

1. Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M. Neuroprotective Effects of Tripeptides -- Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals. 2021. PMID: 34071923. DOI: 10.3390/ph14060515. ↩ ↩²